JP2023526495A5 - - Google Patents
Info
- Publication number
- JP2023526495A5 JP2023526495A5 JP2022571114A JP2022571114A JP2023526495A5 JP 2023526495 A5 JP2023526495 A5 JP 2023526495A5 JP 2022571114 A JP2022571114 A JP 2022571114A JP 2022571114 A JP2022571114 A JP 2022571114A JP 2023526495 A5 JP2023526495 A5 JP 2023526495A5
- Authority
- JP
- Japan
- Prior art keywords
- sars
- cov
- sequence
- seq
- spike
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063027283P | 2020-05-19 | 2020-05-19 | |
| US63/027,283 | 2020-05-19 | ||
| US202063047789P | 2020-07-02 | 2020-07-02 | |
| US63/047,789 | 2020-07-02 | ||
| US202163139292P | 2021-01-19 | 2021-01-19 | |
| US63/139,292 | 2021-01-19 | ||
| PCT/US2021/033275 WO2021236854A1 (en) | 2020-05-19 | 2021-05-19 | Sars-cov-2 vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526495A JP2023526495A (ja) | 2023-06-21 |
| JP2023526495A5 true JP2023526495A5 (enExample) | 2024-05-27 |
Family
ID=78707614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571114A Pending JP2023526495A (ja) | 2020-05-19 | 2021-05-19 | ＳＡＲＳ－ＣｏＶ－２ワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230330215A1 (enExample) |
| EP (1) | EP4153730A4 (enExample) |
| JP (1) | JP2023526495A (enExample) |
| KR (1) | KR20230025670A (enExample) |
| CN (1) | CN116437951A (enExample) |
| AU (1) | AU2021273827A1 (enExample) |
| CA (1) | CA3178115A1 (enExample) |
| IL (1) | IL297795A (enExample) |
| WO (1) | WO2021236854A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| JP2023550094A (ja) * | 2020-11-12 | 2023-11-30 | ティースキャン セラピューティクス インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用 |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| WO2022221189A1 (en) * | 2021-04-12 | 2022-10-20 | La Jolla Institute For Immunology | Coronavirus t cell epitopes and uses thereof |
| WO2022268916A2 (en) * | 2021-06-23 | 2022-12-29 | Ose Immunotherapeutics | Pan-coronavirus peptide vaccine |
| WO2023081936A2 (en) * | 2021-11-08 | 2023-05-11 | Gritstone Bio, Inc. | Sars-cov-2 vaccines |
| CN116212012A (zh) * | 2021-12-02 | 2023-06-06 | 上海泽润生物科技有限公司 | 复合佐剂以及包含它的疫苗制剂 |
| WO2023100159A2 (en) * | 2021-12-03 | 2023-06-08 | Kashiv Biosciences, Llc | Multicistron expression vector for covid-19 vaccine |
| TWI845133B (zh) * | 2022-01-27 | 2024-06-11 | 中央研究院 | 胜肽介導的活性劑遞送 |
| CN114907453B (zh) * | 2022-04-08 | 2023-07-25 | 国科宁波生命与健康产业研究院 | 一种用于治疗SARS-CoV-2病毒感染的S蛋白多肽 |
| CN114832099B (zh) * | 2022-04-08 | 2023-11-28 | 国科宁波生命与健康产业研究院 | 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂 |
| CN119563028A (zh) * | 2022-05-12 | 2025-03-04 | 尚威天成信使核糖核酸治疗公司 | 具有分泌抗原和免疫调节物的合成自扩增mRNA分子 |
| CA3259040A1 (en) * | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| WO2024026553A1 (en) * | 2022-08-03 | 2024-02-08 | Centre Hospitalier De L'université De Montréal | Novel antigenic epitope against sars-cov-2 and uses thereof |
| WO2024061188A1 (zh) * | 2022-09-19 | 2024-03-28 | 百奥泰生物制药股份有限公司 | 一种冠状病毒多价疫苗及其应用 |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2970865T3 (es) * | 2015-12-16 | 2024-05-31 | Gritstone Bio Inc | Identificación, fabricación y uso de neoantígenos |
-
2021
- 2021-05-19 KR KR1020227044348A patent/KR20230025670A/ko active Pending
- 2021-05-19 CA CA3178115A patent/CA3178115A1/en active Pending
- 2021-05-19 CN CN202180049931.9A patent/CN116437951A/zh active Pending
- 2021-05-19 JP JP2022571114A patent/JP2023526495A/ja active Pending
- 2021-05-19 IL IL297795A patent/IL297795A/en unknown
- 2021-05-19 EP EP21808924.1A patent/EP4153730A4/en active Pending
- 2021-05-19 AU AU2021273827A patent/AU2021273827A1/en active Pending
- 2021-05-19 WO PCT/US2021/033275 patent/WO2021236854A1/en not_active Ceased
-
2022
- 2022-11-18 US US18/057,171 patent/US20230330215A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526495A5 (enExample) | ||
| JP2021525076A5 (enExample) | ||
| JP2023541108A5 (enExample) | ||
| US20230330215A1 (en) | Sars-cov-2 vaccines | |
| JP2022512912A5 (enExample) | ||
| JP2022539417A5 (enExample) | ||
| JP2021524247A5 (enExample) | ||
| JP2021525076A (ja) | 共有抗原 | |
| JP2022534282A5 (enExample) | ||
| JP2022512912A (ja) | アルファウイルス新生抗原ベクター及びインターフェロン阻害因子 | |
| JP2021524247A (ja) | 免疫チェックポイント阻害剤の共発現ベクター | |
| JP2023521662A5 (enExample) | ||
| RU2019119272A (ru) | Вирусная доставка неоантигенов | |
| JP2023523414A5 (enExample) | ||
| JP2023523413A5 (enExample) | ||
| JP2024503108A5 (enExample) | ||
| WO2022159511A2 (en) | Modified alphavirus vectors | |
| JP2024542126A5 (enExample) | ||
| CN120888569A (zh) | 一种自复制mRNA疫苗及其制备方法和用途 | |
| US20250121052A1 (en) | Sars-cov-2 vaccines | |
| KR20240099144A (ko) | 신생항원 보조 및 유지 요법 | |
| JP2023553014A5 (enExample) | ||
| US20240238412A1 (en) | Pancoronavirus vaccines | |
| RU2019138741A (ru) | Неоантигенные векторы на основе альфавируса | |
| WO2026030253A1 (en) | Human papillomavirus (hpv) vaccines |